Published in Br J Cancer on January 01, 1974
Augmentation of cytotoxic drug action and X-irradiation by antibodies. Br J Cancer (1975) 0.81
ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response. Br J Cancer (1979) 0.79
A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells/. Nature (1994) 2.35
Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Br J Cancer (1977) 2.31
UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim (1988) 1.95
Antitumour activity in a series of bisdiketopiperazines. Nature (1969) 1.89
Repopulation of gamma-irradiated Lewis lung carcinoma by malignant cells and host macrophage progenitors. Br J Cancer (1978) 1.77
Cell survival in B16 melanoma after treatment with combinations of cytotoxic agents: lack of potentiation. Br J Cancer (1977) 1.51
Cell yield and cell survival following chemotherapy of the B16 melanoma. Br J Cancer (1978) 1.30
Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole. Br J Cancer (1981) 1.23
Dose-rate effects and the repair of radiation damage. Radiother Oncol (1986) 1.09
Influence of anaesthetics on tumour-cell kill and repopulation in B16 melanoma treated with melphalan. Br J Cancer (1978) 1.09
Effect of environmental temperature on the kinetic properties of goldfish brain choline acetyltransferase. Biochem J (1972) 1.03
ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer (1995) 1.02
Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res (1997) 1.00
Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res (1998) 0.98
Influence of in vitro assay conditions on the assessment of radiobiological parameters of the MT tumour. Br J Radiol (1980) 0.97
Clonogenic assays in the B16 melanoma: response to cyclophosphamide. Br J Cancer (1977) 0.97
Development of drug resistance in a murine mammary tumour. Br J Cancer (1985) 0.96
Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha. Mol Pharmacol (2000) 0.94
Mutations at the stromal processing peptidase cleavage site of a thylakoid lumen protein precursor affect the rate of processing but not the fidelity. J Biol Chem (1994) 0.89
A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol (1995) 0.88
The effect of cytotoxic drugs with or without misonidazole on leucopenia in three strains of mice. Int J Radiat Oncol Biol Phys (1982) 0.88
Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol (1997) 0.85
Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site. Mol Pharmacol (1997) 0.85
An explanation for the ability of cytotoxic drug pretreatment to reduce bone marrow related lethality of total body irradiation (TBI). Int J Radiat Oncol Biol Phys (1982) 0.84
Clonal variation in the sensitivity of B16 melanoma to m-AMSA. Br J Cancer (1982) 0.84
Response of two mouse tumours to hyperthermia with CCNU or melphalan. Br J Cancer (1982) 0.83
Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action. J Cell Sci (1997) 0.83
Identification of a subpopulation of MeCCNU resistant cells in previously untreated Lewis lung tumours. Br J Cancer (1984) 0.83
Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase II and [gamma-32P]-ATP. Nat Biotechnol (1996) 0.83
The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Cancer Chemother Pharmacol (1992) 0.82
Enhancement of cytotoxic drugs by misonidazole (MISO) in Lewis lung tumors of different sizes, and mouse bone marrow. Int J Radiat Oncol Biol Phys (1982) 0.82
Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice. J Pharmacol Exp Ther (1996) 0.81
Continuous irradiation of the Lewis lung carcinoma in vivo at clinically-used "ultra" low-dose-rates. Int J Radiat Oncol Biol Phys (1983) 0.80
Recombinant anti-human melanoma antibodies are versatile molecules. J Invest Dermatol (1996) 0.80
Emergence of nitrosourea resistant sublines of Lewis lung tumour following MeCCNU treatment in vivo. Br J Cancer (1986) 0.79
Development of MeCCNU-resistance in clonally derived lines of Lewis lung carcinoma. Eur J Cancer Clin Oncol (1987) 0.79
Biochemical studies on growth-inhibitory bisdioxopiperazines. I. Effect on DNA, RNA and protein synthesis in mouse-embryo fibroblasts. Int J Cancer (1970) 0.79
Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds. Br J Cancer (1999) 0.79
Radiosensitivity of the B16 melanoma is not significantly influenced by melanin content. Int J Radiat Biol Relat Stud Phys Chem Med (1986) 0.78
Split-dose and low dose-rate recovery in four experimental tumour systems. Int J Radiat Biol Relat Stud Phys Chem Med (1987) 0.78
Substituted-2-desamino-2-methyl-quinazolinones. A series of novel antitumour agents. Adv Exp Med Biol (1993) 0.78
Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Eur J Cancer (2002) 0.78
The effect of bisdioxopiperazines on the synthesis of deoxyribonucleic acid, ribonucleic acid and protein in growing mouse-embryo fibroblasts. Biochem J (1969) 0.77
Response to continuous irradiation (CI) in relation to the initial slope of the cell survival curve for tumours and bone marrow. Br J Cancer Suppl (1984) 0.77
Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. Br J Cancer (2008) 0.77
Gamma-linked dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8- dideazafolate as antitumour agents. Adv Exp Med Biol (1993) 0.77
Metal binding by pharmaceuticals. Part 5. Interaction of Cd(II), Ni(II) and Pb(II) with the intracellular hydrolysis products of the anti-tumour agent ICRF 159 and its inactive homologue ICRF 192. Agents Actions (1984) 0.77
Temporal interactions in the Lewis lung tumour between cytotoxic drugs and acute or fractionated radiotherapy. Radiother Oncol (1986) 0.77
Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192. Agents Actions (1982) 0.77
Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters. Res Commun Chem Pathol Pharmacol (1985) 0.76
Clonal variation in the sensitivity of a murine mammary carcinoma to melphalan. Br J Cancer (1986) 0.75
Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: a method for labelling antibodies with 32P. Br J Cancer (1988) 0.75
Comparison of growth delay and cell survival as end-points of tumour response following treatment with combinations of cytotoxic agents. Br J Cancer Suppl (1980) 0.75
ICRF 159-induced cell-cycle perturbation in vitro: its relationship to inhibition of colony-forming ability. Br J Cancer (1981) 0.75
ICI D1694, an inhibitor of thymidylate synthase for clinical study. Adv Exp Med Biol (1991) 0.75
Kinetics of cellular inactivation by fractionated and hyperfractionated irradiation in Lewis lung carcinoma. Int J Radiat Oncol Biol Phys (1985) 0.75
Adriamycin sensitivity following "ultra" low dose rate irradiation of Lewis lung carcinoma in vivo. Int J Radiat Oncol Biol Phys (1985) 0.75
Efficient but aberrant cleavage of mitochondrial precursor proteins by the chloroplast stromal processing peptidase. Eur J Biochem (1994) 0.75
Leukaemia associated with razoxane. Lancet (1982) 0.75
Letter: ICRF 159. Lancet (1974) 0.75
CONCERTED BEHAVIOR OF TERRESTRIAL MOLLUSKS. Science (1918) 0.75
Inheritance of cellular resistance to the antitumor agent ICRF 159 in somatic cell hybrids. J Natl Cancer Inst (1982) 0.75